keyword
MENU ▼
Read by QxMD icon Read
search

Cutaneous T cell Lymphoma

keyword
https://www.readbyqxmd.com/read/28220931/the-role-of-extracorporeal-photopheresis-in-the-management-of-cutaneous-t-cell-lymphoma-graft-versus-host-disease-and-organ-transplant-rejection-a-consensus-statement-update-from-the-uk-photopheresis-society
#1
Arun Alfred, Peter C Taylor, Fiona Dignan, Khaled El-Ghariani, James Griffin, Andrew R Gennery, Denise Bonney, Emma Das-Gupta, Sarah Lawson, Ram K Malladi, Kenneth W Douglas, Tracey Maher, Julie Guest, Laura Hartlett, Andrew J Fisher, Fiona Child, Julia J Scarisbrick
Extracorporeal photopheresis (ECP) has been used for over 35 years in the treatment of erythrodermic cutaneous T-cell lymphoma (CTCL) and over 20 years for chronic and acute graft-versus-host disease (GvHD) and solid organ transplant rejection. ECP for CTCL and GvHD is available at specialised centres across the UK. The lack of prospective randomised trials in ECP led to the development of UK Consensus Statements for patient selection, treatment schedules, monitoring protocols and patient assessment criteria for ECP...
February 21, 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/28218382/primary-cutaneous-non-hodgkin-lymphoma-results-of-a-retrospective-analysis-in-the-light-of-the-recent-ilrog-guidelines
#2
Sara Pedretti, Mauro Urpis, Carla Leali, Paolo Borghetti, Liliana Baushi, Raffaella Sala, Alessandra Tucci, Diana Greco, Nadia Pasinetti, Luca Triggiani, Giuseppe Rossi, Piergiacomo Calzavara-Pinton, Stefano Maria Magrini, Michela Buglione
PURPOSE: To analyze clinical outcome, local response, survival and toxicity in patients with primary cutaneous lymphoma (PCL) treated with radiotherapy. METHODS: From 1995 to 2014, 112 patients were treated. B-cell lymphomas (CBCLs; n = 86) and T-cell lymphomas (CTCLs; n = 23) were analyzed separately. Clinical and therapeutic characteristics (age, sex, histology, primary treatment and radiotherapy modality) were related to response to treatment, survival and toxicity...
February 14, 2017: Tumori
https://www.readbyqxmd.com/read/28199478/evaluation-of-o6-benzylguanine-potentiated-topical-carmustine-for-mycosis-fungoides-a-phase-1-2-clinical-trial
#3
Joselin D Tacastacas, Derek V Chan, Sean Carlson, Stanton L Gerson, Afshin Dowlati, Pingfu Fu, Kurt Lu, Sarah Groft, Julie Rosenjack, Kord Honda, Thomas McCormick, Kevin D Cooper
Importance: In a phase 1 trial, single-dose O6-benzylguanine with topical carmustine for patients with early stage (stage IA through stage IIA) cutaneous T-cell lymphoma, mycosis fungoides (MF) type, resulted in clinical responses proportional to inhibition of O6-alkylguanine DNA alkyltransferase activity, but a maximum tolerated dose (MTD) was not reached. Objective: To determine whether dose escalation of carmustine in combination with dual-dose O6-benzylguanine to prolong alkyltransferase inhibition could reach an MTD...
February 15, 2017: JAMA Dermatology
https://www.readbyqxmd.com/read/28196286/psoralen-with-ultraviolet-a-puva-induced-apoptosis-of-cutaneous-lymphoma-cell-lines-is-augmented-by-type-i-interferons-via-the-jak1-stat1-pathway
#4
Walter Liszewski, David Gram Naym, Edyta Biskup, Robert Gniadecki
BACKGROUND: Photochemotherapy with psoralen and ultraviolet A (PUVA), with or without adjuvant interferon-α (IFN-α), is a first line therapy for early stage mycosis fungoides and other forms of cutaneous T-cell lymphoma (CTCL). However, the mechanism by which PUVA with IFN-α work in CTCL is poorly understood. PURPOSE: To develop a model to investigate the mechanisms of PUVA and PUVA with IFN-α in CTCL cells. METHODS: An in vitro model to study the molecular mechanisms of PUVA was created using two different CTCL cell lines, MyLa, which has functional p53, and HuT-78, in which p53 is inactivated due to a homozygous nonsense mutation...
February 14, 2017: Photodermatology, Photoimmunology & Photomedicine
https://www.readbyqxmd.com/read/28187925/aggressive-cutaneous-t-cell-lymphomas
#5
Jacqueline M Junkins-Hopkins Md
Cutaneous T cell lymphomas (CTCLs) are heterogeneous, with a prognosis determined in large part by combined clinical, histopathologic, and immunophenotypic features. They are classified under the WHO-EORTC classification of primary cutaneous lymphoma. Whether or not a patient diagnosed with CTCL will experience an aggressive course may not be completely predictable; however, certain subtypes have been proven to be associated with a poor response to therapy and/or short survival. These aggressive subtypes may be diagnosed by certain histologic, immunophenotypic, and clinical features; however, there are benign lymphoproliferative disorders (LPD), such as lymphomatoid papulosis (LyP) that present with biopsy findings that simulate an aggressive lymphoma...
December 24, 2016: Seminars in Diagnostic Pathology
https://www.readbyqxmd.com/read/28181261/the-search-for-potent-small-molecule-hdacis-in-cancer-treatment-a-decade-after-vorinostat
#6
REVIEW
Chiara Zagni, Giuseppe Floresta, Giulia Monciino, Antonio Rescifina
Histone deacetylases (HDACs) play a crucial role in the remodeling of chromatin, and are involved in the epigenetic regulation of gene expression. In the last decade, inhibition of HDACs came out as a target for specific epigenetic changes associated with cancer and other diseases. Until now, more than 20 HDAC inhibitors (HDACIs) have entered clinical studies, and some of them (e.g., vorinostat, romidepsin) have been approved for the treatment of cutaneous T-cell lymphoma. This review provides an overview of current knowledge, progress, and molecular mechanisms of HDACIs, covering a period from 2011 until 2015...
February 9, 2017: Medicinal Research Reviews
https://www.readbyqxmd.com/read/28176301/phenotypic-analysis-of-circulating-t-cell-subset-and-its-association-with-burden-of-skin-disease-in-patients-with-chronic-actinic-dermatitis-a-hematologic-and-clinicopathologic-study-of-20-subjects
#7
Toshihisa Hamada, Yumi Aoyama, Yoshinori Shirafuji, Keiji Iwatsuki
BACKGROUND: Chronic actinic dermatitis (CAD) is a recurrent photosensitive dermatitis that occurs predominantly on sun-exposed areas with unknown etiology. In severe cases, it may present with erythroderma, which is clinicopathologically analogous to cutaneous T-cell lymphoma. Typically, inflammatory infiltrates in the skin lesions are mainly CD8(+) reactive T cells. However, hematologic characteristics of CAD have not been fully elucidated. METHODS: Twenty patients with CAD ranging in age from 45 to 86 years (median, 64), including 17 males and three females (M/F ratio, 5...
February 7, 2017: International Journal of Dermatology
https://www.readbyqxmd.com/read/28175924/morbidity-and-causes-of-death-in-patients-with-cutaneous-t-cell-lymphoma-in-finland
#8
Liisa Väkevä, Tuomas Lipsanen, Harri Sintonen, Annamari Ranki
Cutaneous T-cell lymphomas (CTCL), especially mycosis fungoides, can be considered as a state of longstanding low-grade systemic inflammation. Many studies have focused on secondary cancers with CTCL, but information about comorbidities is limited. A total of 144 patients with CTCL at Helsinki University Central Hospital during 2005 to 2015 were studied to determine associated comorbidities and causes of death in this cohort. Compared with an age-standardized control population, the prevalence of type 2 diabetes mellitus was increased among patients with CTCL with no link to obesity...
February 8, 2017: Acta Dermato-venereologica
https://www.readbyqxmd.com/read/28175923/cutaneous-gamma-delta-t-cell-lymphoma-with-an-initially-indolent-course-mimicking-lupus-panniculitis
#9
Johannes Benecke, Cyrill Géraud, Jan P Nicolay
is missing (Short communication).
February 8, 2017: Acta Dermato-venereologica
https://www.readbyqxmd.com/read/28169015/janus-kinase-inhibitors-in-dermatology-a-systematic-review
#10
REVIEW
Rony Shreberk-Hassidim, Yuval Ramot, Abraham Zlotogorski
BACKGROUND: Janus kinase (JAK) inhibitors are emerging as a promising new treatment modality for many inflammatory conditions. OBJECTIVE: Our aim was to systematically review the available data on the use of JAK inhibitors in cutaneous diseases. METHODS: This is a systematic review of PubMed and ClinicalTrials.gov. RESULTS: One hundred thirty-four articles matched our search terms, of which 78 were original articles and 12 reports on adverse events...
February 3, 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28167509/results-from-a-phase-i-ii-open-label-dose-finding-study-of-pralatrexate-and-oral-bexarotene-in-patients-with-relapsed-refractory-cutaneous-t-cell-lymphoma
#11
Madeleine Duvic, Youn H Kim, Pier Luigi Zinzani, Steven Horwitz
PURPOSE: Pralatrexate is a folic acid analog metabolic inhibitor similar to methotrexate,that has shown tolerability and efficacy with an overall response rate of 45% in a phase 1 dose de-escalation study of patients with relapsed/refractory cutaneous T-cell lymphoma CTCL. EXPERIMENTAL DESIGN: The object of this phase I/II open-label, multi-center clinical trial was to determine the maximum tolerated dose (MTD) and recommended dose of pralatrexate plus oral bexarotene in 34 patients with relapsed/refractory CTCL who had failed prior systemic therapies...
February 6, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28153507/expression-of-p63-protein-in-anaplastic-large-cell-lymphoma-implications-for-genetic-subtyping
#12
Xueju Wang, Rebecca L Boddicker, Surendra Dasari, Jagmohan S Sidhu, Marshall E Kadin, William R Macon, Stephen M Ansell, Rhett P Ketterling, Karen L Rech, Andrew L Feldman
Anaplastic large cell lymphomas (ALCLs) are CD30-positive T-cell non-Hodgkin lymphomas that bear chromosomal rearrangements of the TP53 homologue, TP63, in a subset of cases that demonstrate aggressive clinical behavior. In the present study, we examined the relationship between p63 protein expression by immunohistochemistry and the results of fluorescence in situ hybridization (FISH) using TP63 probes in 116 ALCLs. We also determined the relative expression of full-length TAp63 and truncated ΔNp63 isoforms (e...
January 30, 2017: Human Pathology
https://www.readbyqxmd.com/read/28151793/igg4-expression-in-primary-cutaneous-marginal-zone-lymphoma-a-multicenter-study
#13
Aieska De Souza, Judith A Ferry, Daniel R Burghart, Marianne Tinguely, Amrita Goyal, Lyn M Duncan, Heinz Kutzner, Werner Kempf
BACKGROUND: Primary cutaneous marginal zone lymphoma (PCMZL) is the second most common B-cell lymphoma of the skin. A recent study has demonstrated a strikingly high prevalence of immunoglobulin (Ig)G4 expression in PCMZL with plasmacytic differentiation. OBJECTIVE: The objective was to investigate the incidence of IgG4 expression in PCMZL, and its correlation with clinical and immunophenotypic features. MATERIALS AND METHODS: Multicenter study that utilized immunohistochemistry and in-situ hybridization to evaluate the expression of IgG4, Ig light (κ and λ), and heavy chains (IgM, IgG), and the ratio of T (CD3+) and B (CD20+) cells in biopsy specimens from 30 patients with PCMZL and to correlate these findings with the clinical features...
February 1, 2017: Applied Immunohistochemistry & Molecular Morphology: AIMM
https://www.readbyqxmd.com/read/28134730/primary-cutaneous-follicular-helper-t-cell-lymphoma-in-a-patient-with-neurofibromatosis-type-1-case-report-and-review-of-the-literature
#14
REVIEW
Anastasia Shamsuyarova, Zaid Kamil, Jan Delabie, Nadya Al-Faraidy, Danny Ghazarian
Patients with neurofibromatosis type 1 (NF-1) have a well-known predisposition for certain types of malignancies, including lymphoproliferative disorders. Cutaneous T-cell lymphoma (CTCL) has been reported in patients with NF-1, although it is considered a rare entity in this subset of patients. Cutaneous follicular helper T-cell lymphoma (CTFHCL) is a recently emerged rare subtype of CTCL with peculiar clinical and histopathological features and represents a diagnostic and therapeutic challenge. Only a few cases of CTFHCL have been reported in the literature...
February 2017: American Journal of Dermatopathology
https://www.readbyqxmd.com/read/28128277/primary-cutaneous-aggressive-epidermotropic-cytotoxic-t-cell-lymphomas-reappraisal-of-a-provisional-entity-in-the-2016-who-classification-of-cutaneous-lymphomas
#15
Joan Guitart, M Estela Martinez-Escala, Antonio Subtil, Madeleine Duvic, Melissa P Pulitzer, Elise A Olsen, Ellen Kim, Alain H Rook, Sara S Samimi, Gary S Wood, Michael Girardi, Jacqueline Junkins-Hopkins, Doina S Ivan, M Angelica Selim, Kimberly A Sable, Pooja Virmani, Laura B Pincus, Michael T Tetzlaff, Jinah Kim, Youn H Kim
Primary cutaneous CD8-positive aggressive epidermotropic T-cell lymphoma is a rare and poorly characterized variant of cutaneous lymphoma still considered a provisional entity in the latest 2016 World Health Organization Classification of Cutaneous lymphomas. We sought to better characterize and provide diagnostic and therapeutic guidance of this rare cutaneous lymphoma. Thirty-four patients with a median age of 77 years (range 19-89 years) presented primarily with extensive annular necrotic plaques or tumor lesions with frequent mucous membrane involvement...
January 27, 2017: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
https://www.readbyqxmd.com/read/28123457/coronary-and-peripheral-artery-aneurysms-in-a-patient-with-cutaneous-t-cell-lymphoma
#16
Hideki Yasutake, Yoshihiko Ikeda, Osami Kawarada
No abstract text is available yet for this article.
2017: Heart Asia
https://www.readbyqxmd.com/read/28119994/placental-growth-factor-and-vascular-endothelial-growth-factor-together-regulate-tumour-progression-via-increased-vasculature-in-cutaneous-t-cell-lymphoma
#17
Tomomitsu Miyagaki, Makoto Sugaya, Tomonori Oka, Naomi Takahashi, Makiko Kawaguchi, Hiraku Suga, Hideki Fujita, Ayumi Yoshizaki, Yoshihide Asano, Shinichi Sato
Angiogenesis is regarded as an essential step in supporting tumour growth and metastasis. In haematological malignancies, including cutaneous T cell lymphoma (CTCL), angiogenesis is increased and serum levels of some pro-angiogenic markers are elevated. The aim of this study was to investigate expression levels of placental growth factor (PlGF) and vascular endothelial growth factor (VEGF)-A in lesional skin and sera in patients with CTCL, and to assess the association of these factors with development of CTCL...
January 25, 2017: Acta Dermato-venereologica
https://www.readbyqxmd.com/read/28119332/brentuximab-beats-standard-therapies-for-ctcl
#18
(no author information available yet)
Compared with a physician's choice of either methotrexate or bexarotene, the CD30-directed antibody-drug conjugate brentuximab vedotin led to significantly superior clinical responses in patients with cutaneous T-cell lymphomas, according to the results of the international phase III ALCANZA trial.
January 24, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28107479/apoptosis-induction-and-gene-expression-profile-alterations-of-cutaneous-t-cell-lymphoma-cells-following-their-exposure-to-bortezomib-and-methotrexate
#19
Vassiliki Mpakou, Evangelia Papadavid, Frieda Kontsioti, Eugene Konsta, Miriam Vikentiou, Aris Spathis, Sotiris Papageorgiou, Diamantina Vasilatou, Konstantinos Gkontopoulos, Efthimia Mpazani, Petros Karakitsos, Dimitrios Rigopoulos, George Dimitriadis, Vasiliki Pappa
Mycosis fungoides (MF) and its leukemic variant Sézary syndrome (SS) comprise the majority of CTCL, a heterogenous group of non-Hodgkins lymphomas involving the skin. The CTCL's resistance to chemotherapy and the lack of full understanding of their pathogenesis request further investigation. With the view of a more targeted therapy, we evaluated in vitro the effectiveness of bortezomib and methotrexate, as well as their combination in CTCL cell lines, regarding apoptosis induction. Our data are of clinical value and indicate that the bortezomib/methotrexate combinational therapy has an inferior impact on the apoptosis of CTCL compared to monotherapy, with bortezomib presenting as the most efficient treatment option for SS and methotrexate for MF...
2017: PloS One
https://www.readbyqxmd.com/read/28106877/investigating-heredity-in-cutaneous-t-cell-lymphoma-in-a-unique-cohort-of-danish-twins
#20
N Odum, L M Lindahl, M Wod, T Krejsgaard, A Skytthe, A Woetmann, L Iversen, K Christensen
No abstract text is available yet for this article.
January 20, 2017: Blood Cancer Journal
keyword
keyword
6668
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"